It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.

A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.

GSK added ROS1 inhibitor to its pipeline through its $10.6 billion acquisition of Nuvalent earlier this month.

A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The firm reported that two Phase III trials of Redemplo met their primary endpoints of lowering patients' triglyceride levels.

The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.